Conference on Retroviruses and Opportunistic Infections (CROI)

Healio brings you the highlights from the Conference on Retroviruses and Opportunistic Infections (CROI). Refer back to this page often for the latest news from CROI, perspectives and interviews with leading researchers and clinicians, and to review archives of past meetings.

Meeting NewsPerspective

Zika RNA persists in serum longer than dengue, West Nile

February 16, 2017
SEATTLE — Preliminary study results showed that Zika RNA may persist in serum longer than other flaviviruses such as dengue and West Nile…
Meeting NewsPerspective

New HIV infections decline 18% in US

February 15, 2017
SEATTLE —The overall number of annual HIV infections in the United States declined 18% over a 6-year period, with approximately 45,700 new…
Meeting News

New TB regimens promise to simplify, shorten therapy

February 15, 2017
SEATTLE — Two novel tuberculosis treatment regimens comprising the same backbone of Sirturo and the experimental pretomanid are showing promise…

Virologic response to ART varies among HIV–infected infants

February 15, 2017
SEATTLE — Virologic response to early ART differs among HIVinfected neonates, suggesting that clinical and social challenges influence…
Meeting News

For HIV–positive women, cryotherapy less effective than LEEP in fighting cervical precancer

February 15, 2017
SEATTLE — Cryotherapy was associated with a significantly higher risk of recurrence of cervical precancer in women with HIV than a costlier…
Meeting News

ART, male circumcision drives down HIV incidence in Uganda

February 15, 2017
SEATTLE — A Ugandan community with an historically significant place in the HIV/AIDS epidemic in Africa experienced a substantial long-term…
Meeting News

Two-drug HIV regimen noninferior to multidrug regimen

February 14, 2017
SEATTLE — A two-drug regimen for treating HIV-1 could become an alternative to three- or four-drug regimens in the future, according to a pair…
Meeting NewsVideo

VIDEO: CROI 2017 Overview

February 14, 2017
SEATTLE — In a brief overview, CROI 2017 Vice Chair Judith S. Currier, MD, professor of medicine and division chief of infectious diseases at…
Meeting NewsPerspective

New HIV integrase inhibitor shows promise in phase 2 trial

February 14, 2017
SEATTLE — Results from a phase 2 randomized clinical trial show that Gilead Sciences’ investigational HIV drug bictegravir was both…

Infectious Disease News prepares for CROI 2017

February 13, 2017
SEATTLE — Infectious Disease News and Healio.com/ID will offer live coverage from the annual Conference on Retroviruses and Opportunistic…